![Figure 4. VH peptide–pulsed DC vaccination induces a protective immune response in vivo. This is a compilation of data from 3 independent experiments, each of which showed similar results. In the VH group (n = 15 mice) mice were vaccinated intraperitoneally with DCs pulsed with 3 germ line MHC class I peptides (A9T[Fr3], K9I[Fr2/CDR2], S9L[Fr3]) and 3 germ line MHC class II VH peptides (G16K[Leader/Fr1], F17L[Fr1/CDR1/Fr2], A15V[Fr3]) derived from the VH of the 1H6 murine lymphoma cell line and shown to be immunogenic in vitro, on days 1, 14, and 21. In the control group (n = 14 mice) mice were not vaccinated. On day 24, mice in all groups were challenged subcutaneously with 2.5 × 104 1H6 cells grown in serum-free hybridoma medium. Tumors were measured weekly, and the proportion of tumor-free mice is presented. The Kaplan Meier distributions of tumor-free mice for the VH group were significantly higher than that of the nonvaccinated control mice (control vs VH; P < .001). There was a significant decrease in the distribution of tumor-free mice in a group of mice (n = 15) treated with non–peptide-pulsed DCs alone, compared to that of the VH group (P = .007; data not shown).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/104/3/10.1182_blood-2004-01-0105/6/zh80150464350004.jpeg?Expires=1723375066&Signature=AaR0M4tf0V7TdlJnkze59XPbE6QLMW4~EqMm7cn8ZUu7Hih2TaqL3vO6FXE19wZyHemNomHA27wdFnCBfITjnQk1Z0F2-pQX3rdN8jHN8XaZzI2bQJWQSmVT6ITx6y3N9Le12VK-k9~XikTiFbTnajAUeVz4jq4IDH9mzJ~G3~NuCVFE1Kdtys0wRhY2BUTRBdePoeUJNXuIImDg0pFbR75RYMz2VxLkVyBlQh7zezWf7wsGEZT8V3bgaCFhK~ZJIxLiQV2ji176ME-W85I8JLH0FEuGmIWrN3z2yT-4mLqhOI-VWAqvty7jdQJvweko2CyFP3mP6NWSCTfMJ3aPNQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
VH peptide–pulsed DC vaccination induces a protective immune response in vivo. This is a compilation of data from 3 independent experiments, each of which showed similar results. In the VH group (n = 15 mice) mice were vaccinated intraperitoneally with DCs pulsed with 3 germ line MHC class I peptides (A9T[Fr3], K9I[Fr2/CDR2], S9L[Fr3]) and 3 germ line MHC class II VH peptides (G16K[Leader/Fr1], F17L[Fr1/CDR1/Fr2], A15V[Fr3]) derived from the VH of the 1H6 murine lymphoma cell line and shown to be immunogenic in vitro, on days 1, 14, and 21. In the control group (n = 14 mice) mice were not vaccinated. On day 24, mice in all groups were challenged subcutaneously with 2.5 × 104 1H6 cells grown in serum-free hybridoma medium. Tumors were measured weekly, and the proportion of tumor-free mice is presented. The Kaplan Meier distributions of tumor-free mice for the VH group were significantly higher than that of the nonvaccinated control mice (control vs VH; P < .001). There was a significant decrease in the distribution of tumor-free mice in a group of mice (n = 15) treated with non–peptide-pulsed DCs alone, compared to that of the VH group (P = .007; data not shown).
